Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Q4 2022 Earnings Call Transcript

Joe Ciaffoni: Yes, so Greg, this is Joe, I appreciate the question. Look, I’m not going to prognosticate on that. What I would say to you is we believe on a full year basis. Both BELBUCA and Xtampza ER will grow prescriptions in 2023. As I said in my prepared remarks, I’m encouraged by the start we’re off to in 2023. And I would say at this point, there’s no surprises. Everything is tracking in line to our expectations.

Greg Fraser: Got it. Okay, and can you talk a bit more about the initiatives they span party coverage for BELBUCA? Are you thinking to sign contracts this year that will help next year and beyond? And will you try to maintain the gross and net below us for a certain level as you add party lines?

Joe Ciaffoni: Yes, so I’ll pass that question off to Scott.

Scott Dreyer: Yes. Thanks, Greg. So yes, so for BELBUCA it’s very straightforward. And when we look at this portfolio that we’ve acquired, I mean, BDSI did a great job managing both and managing the gross to net. What we see as the leader responsible pain management is people need access to this product. And Part D is an avenue for that. So it’s early, we’re engaged with payers, we’re telling the clinical story of buprenorphine overall, and BELBUCA in the differentiation versus the patch. And we’ll see where those conversations go. If we are to win in one of those plans it would be for 2024. Right? So we don’t see that as something that would happen mid cycle, and believe that we can do it in a way that’s controllable when it comes to the gross connect to your question there.

Greg Fraser: Okay, and then just my last question is on the recent CDC recommendations for opioid prescribing, I’m curious if you think whether those recommendations will help boost prescribing or not? Thank you.

Joe Ciaffoni: Yes, Greg, so look, I appreciate the question. I think the commentary I’d give on the CDC guidelines is, we’re glad to see experts step back and look at what it is the original guidelines, the impact of them and providing the necessary clarity for physicians as they treat patients who are living with pain in the most responsible way possible, so that I would keep our comments focus to there, and what’s most important for the care and treatment of the patient and I don’t think from a business perspective there’s any impact that we’ll see as a result of that.

Greg Fraser: Got it. Thank you.

Joe Ciaffoni: You’re welcome. Thank you Greg.

Operator: Thank you. Thank you. There appears to be no additional questions. I’ll hand the floor back to Joe Ciaffoni for closing remarks.

Joe Ciaffoni: Thank you. And thank you everyone for joining the call today. I look forward to updating you on our progress throughout the year and I hope that everybody has a great evening.

Operator: Thank you. And with that we conclude today’s conference call. All parties may disconnect. Have a great evening.